Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502).

Authors: Andrew James Weickhardt, Farshad Foroudi, Nathan Lawrentschuk, Jing Xie, Yi-An Ko, Mark Sidhom, Abhijit Pal, Peter S. Grimison, Alison Yan Zhang, Siobhan Ng, Colin Tang, Elizabeth Jane Hovey, Colin Chen, George Hruby, Alexander David Guminski, Samantha Richelle Oakes, Ciara Conduit, Ben Tran, Ian D. Davis, Dickon Hayne,

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.4577

Source: Full article

---

Abstract

4577